bah-roo

WallStreetWisdom

  • Stop Calling Eli Lilly a Bubble — It’s Building a Healthcare Empire

    Stop Calling Eli Lilly a Bubble — It’s Building a Healthcare Empire

    Ozempic made Novo Nordisk famous. Zepbound and Mounjaro made Eli Lilly a monster. And Wall Street still can’t decide if LLY is a rocket ship or a bubble waiting to pop. Here’s the blunt truth: Eli Lilly isn’t just riding the GLP-1 wave — it owns a massive chunk of it. And that’s why the…

  • Stop Treating Jim Cramer Like an Oracle (He’s a Thermometer)

    Stop Treating Jim Cramer Like an Oracle (He’s a Thermometer)

    Jim Cramer says buy, the stock pops. He trashes a name, it tanks. The real question isn’t what he said about Marvell (MRVL) and Bausch Health (BHC). It’s whether you should treat those calls as gospel—or as contrarian signals. Here’s the blunt answer: Cramer is better at spotting narratives than nailing entry points. And in…

  • Cramer’s Buy Calls Aren’t Alpha — They’re Exit Liquidity

    Cramer’s Buy Calls Aren’t Alpha — They’re Exit Liquidity

    Jim Cramer says buy Marvell and Bausch Health. The real question isn’t whether he’s bullish — it’s whether you should be. Because in 2024, a Cramer buy call isn’t just a recommendation. For some traders, it’s a contrarian indicator. Let’s break this down. Marvell (MRVL): AI Tailwinds — But You’re Paying for Them Marvell is…

  • If Jim Cramer Loves It, You’d Better Check the Exit

    If Jim Cramer Loves It, You’d Better Check the Exit

    Jim Cramer said buy it. So now what? That’s the question every trader should ask when a TV personality pounds the table on a stock. Not because Cramer’s always wrong — he’s not. But because once something becomes a headline trade, the easy money is usually gone. Right now, that tension is playing out in…